

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use AFINITOR safely and effectively. See full prescribing information for AFINITOR.

AFINITOR (everolimus) tablets for oral administration
Initial U.S. Approval: 2009

RECENT MAJOR CHANGES

Indications and Usage, Advanced Pancreatic Neuroendocrine Tumors (1.1), Warnings and Precautions: Non-infectious Pneumonitis (5.1), Infections (5.2), Oral Ulceration (5.3), Renal Failure Events (5.4), Laboratory Tests and Monitoring (5.5) 05/2011
Indications and Usage, Subependymal Giant Cell Astrocytoma (1.3) 10/2010
Dosage and Administration (2) 10/2010
Warnings and Precautions: Non-infectious Pneumonitis (5.1), Infections (5.2), Oral Ulceration (5.3), Drug-drug Interactions (5.6), Hepatic Impairment (5.7), Vaccinations (5.8), Use in Pregnancy (5.9) 10/2010

INDICATIONS AND USAGE

AFINITOR is a kinase inhibitor indicated for the treatment of patients with:

- progressive neuroendocrine tumors of pancreatic origin (PNET) that is unresectable, locally advanced or metastatic. The safety and effectiveness of AFINITOR in the treatment of patients with carcinoid tumors have not been established. (1.1)
- advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.2)
- subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of AFINITOR is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated. (1.3)

DOSAGE AND ADMINISTRATION

Advanced PNET or advanced RCC:

- 10 mg once daily with or without food. (2.1)
- For patients with Child-Pugh class B hepatic impairment, reduce the AFINITOR dose to 5 mg once daily. (2.2)
- If moderate inhibitors of CYP3A4 and/or P-glycoprotein (PgP) are required, reduce the AFINITOR dose to 2.5 mg once daily; if tolerated, consider increasing to 5 mg once daily. (2.2)
- If strong inducers of CYP3A4 are required, increase AFINITOR dose in 5 mg increments to a maximum of 20 mg once daily. (2.2)

SEGA:

- Initial dose based on body surface area with subsequent titration to attain trough concentrations of 5-10 ng/mL. (2.3)
- If moderate inhibitors of CYP3A4 and/or PgP are required, reduce the AFINITOR dose by approximately 50%. Subsequent dosing should be based on therapeutic drug monitoring (TDM). (2.4)
- If strong inducers of CYP3A4 are required, double the AFINITOR dose. Subsequent dosing should be based on TDM. (2.4)

Dose reduction and/or treatment interruption may be needed to manage adverse drug reactions. (2.2, 2.4)

DOSAGE FORMS AND STRENGTHS

2.5 mg, 5 mg, and 10 mg tablets with no score (3)

CONTRAINDICATIONS

Hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients (4)

WARNINGS AND PRECAUTIONS

- Non-infectious pneumonitis: Monitor for clinical symptoms or radiological changes; fatal cases have occurred. Manage by dose reduction or discontinuation until symptoms resolve, and consider use of corticosteroids. (5.1)
- Infections: Increased risk of infections, some fatal. Monitor for signs and symptoms, and treat promptly. (5.2)
- Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common. Management includes mouthwashes (without alcohol or peroxide) and topical treatments. (5.3)
- Renal failure events: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed in patients treated with AFINITOR (5.4).
- Laboratory test alterations: Elevations of serum creatinine, blood glucose, and lipids may occur. Decreases in hemoglobin, neutrophils, and platelets may also occur. Monitor renal function, blood glucose, lipids, and hematologic parameters prior to treatment and periodically thereafter. (5.5)
- Vaccinations: Avoid live vaccines and close contact with those who have received live vaccines. (5.8)
- Use in pregnancy: Fetal harm can occur when administered to a pregnant woman. Apprise women of potential harm to the fetus. (5.9, 8.1)

ADVERSE REACTIONS

Advanced PNET: Most common adverse reactions (incidence $\geq 30\%$) are stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache. (6.1)

Advanced RCC: Most common adverse reactions (incidence $\geq 30\%$) are stomatitis, infections, asthenia, fatigue, cough, and diarrhea. (6.2)

SEGA: Most common adverse reactions (incidence $\geq 30\%$) are stomatitis, upper respiratory tract infection, sinusitis, otitis media, and pyrexia. (6.3)

To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Strong CYP3A4 inhibitors: Avoid concomitant use. (2.2, 2.4, 5.6, 7.1)
- Moderate CYP3A4 and/or PgP inhibitors: If combination is required, use caution and reduce dose of AFINITOR. (2.2, 2.4, 5.6, 7.1)
- Strong CYP3A4 inducers: Avoid concomitant use. If combination cannot be avoided, increase dose of AFINITOR. (2.2, 2.4, 5.6, 7.2)

USE IN SPECIFIC POPULATIONS

- Nursing mothers: Discontinue drug or nursing, taking into consideration the importance of drug to the mother. (8.3)
- Hepatic impairment: AFINITOR should not be used in patients with Child-Pugh class C hepatic impairment. For advanced PNET and advanced RCC patients with Child-Pugh class B hepatic impairment, reduce AFINITOR dose. For SEGA patients with Child-Pugh class B hepatic impairment, adjustment to the starting dose may not be needed; however, subsequent dosing should be based on TDM. (2.2, 2.5, 5.7, 8.7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling

Revised: 05/2011

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Advanced Neuroendocrine Tumors of Pancreatic Origin (PNET)
- 1.2 Advanced Renal Cell Carcinoma (RCC)
- 1.3 Subependymal Giant Cell Astrocytoma (SEGA)

2 DOSAGE AND ADMINISTRATION

- 2.1 Recommended Dose in Advanced Pancreatic Neuroendocrine Tumors and Advanced Renal Cell Carcinoma
- 2.2 Dose Modifications in Advanced Pancreatic Neuroendocrine Tumors and Advanced Renal Cell Carcinoma
- 2.3 Recommended Dose in Subependymal Giant Cell Astrocytoma
- 2.4 Dose Modifications in Subependymal Giant Cell Astrocytoma

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Non-infectious Pneumonitis
- 5.2 Infections
- 5.3 Oral Ulceration
- 5.4 Renal Failure Events
- 5.5 Laboratory Tests and Monitoring
- 5.6 Drug-drug Interactions
- 5.7 Hepatic Impairment
- 5.8 Vaccinations
- 5.9 Use in Pregnancy

6 ADVERSE REACTIONS

- 6.2 Clinical Study Experience in Advanced Renal Cell Carcinoma
- 6.3 Clinical Study Experience in Subependymal Giant Cell Astrocytoma

7 DRUG INTERACTIONS

- 7.1 Agents that may Increase Everolimus Blood Concentrations
- 7.2 Agents that may Decrease Everolimus Blood Concentrations
- 7.3 Agents whose Plasma Concentrations may be Altered by Everolimus

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

- 14.1 Advanced Neuroendocrine Tumors
- 14.2 Advanced Renal Cell Carcinoma
- 14.3 Subependymal Giant Cell Astrocytoma

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

- 17.1 Non-infectious Pneumonitis
- 17.2 Infections
- 17.3 Oral Ulceration
- 17.4 Renal Failure Events
- 17.5 Laboratory Tests and Monitoring
- 17.6 Drug-drug Interactions
- 17.7 Hepatic Impairment
- 17.8 Vaccinations
- 17.9 Pregnancy
- 17.10 Dosing Instructions

* Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Advanced Neuroendocrine Tumors of Pancreatic Origin (PNET)

AFINITOR[®] is indicated for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.

The safety and effectiveness of AFINITOR[®] in the treatment of patients with carcinoid tumors have not been established.

1.2 Advanced Renal Cell Carcinoma (RCC)

AFINITOR[®] is indicated for the treatment of patients with advanced RCC after failure of treatment with sunitinib or sorafenib.

1.3 Subependymal Giant Cell Astrocytoma (SEGA)

AFINITOR[®] is indicated for the treatment of patients with SEGA associated with tuberous sclerosis (TS) who require therapeutic intervention but are not candidates for curative surgical resection.

The effectiveness of AFINITOR is based on an analysis of change in SEGA volume [see *Clinical Studies (14.2)*]. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.

2 DOSAGE AND ADMINISTRATION

AFINITOR should be administered orally once daily at the same time every day, either consistently with food or consistently without food [see *Clinical Pharmacology (12.3)*].

AFINITOR tablets should be swallowed whole with a glass of water. The tablets should not be chewed or crushed. For patients unable to swallow tablets, AFINITOR tablet(s) should be dispersed completely in a glass of water (containing approximately 30 mL) by gently stirring, immediately prior to drinking. The glass should be rinsed with the same volume of water and the rinse should be completely swallowed to ensure that the entire dose is administered.

Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.

2.1 Recommended Dose in Advanced Pancreatic Neuroendocrine Tumors and Advanced Renal Cell Carcinoma

The recommended dose of AFINITOR for treatment of advanced PNET and advanced RCC is 10 mg, to be taken once daily.

Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.

2.2 Dose Modifications in Advanced Pancreatic Neuroendocrine Tumors and Advanced Renal Cell Carcinoma

Management of severe or intolerable adverse reactions may require temporary dose reduction and/or interruption of AFINITOR therapy. If dose reduction is required, the suggested dose is 5 mg daily [see *Warnings and Precautions (5.1)*].

Hepatic Impairment

For patients with moderate hepatic impairment (Child-Pugh class B), reduce the dose to 5 mg daily. AFINITOR has not been evaluated in patients with severe hepatic impairment (Child-Pugh class C) and should not be used in this patient population [see *Warnings and Precautions (5.7)* and *Use in Specific Populations (8.7)*].

CYP3A4 and/or P-glycoprotein (PgP) Inhibitors

Avoid the use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) [see *Warnings and Precautions (5.6)* and *Drug Interactions (7.1)*].

Use caution when co-administered with moderate CYP3A4 and/or PgP inhibitors (e.g., amprenavir, fosamprenavir, aprepitant, erythromycin, fluconazole, verapamil, diltiazem). If patients require co-administration of a moderate CYP3A4 and/or PgP inhibitor, reduce the AFINITOR dose to 2.5 mg daily. The reduced dose of AFINITOR is predicted to adjust the area under the curve (AUC) to the range observed without inhibitors. An AFINITOR dose increase from 2.5 mg to 5 mg may be considered based on patient tolerance. If the moderate inhibitor is discontinued, a washout period of approximately 2 to 3 days should be allowed before the AFINITOR dose is increased. If the moderate inhibitor is discontinued, the AFINITOR dose should be returned to the dose used prior to initiation of the moderate CYP3A4 and/or PgP inhibitor.

Strong CYP3A4 Inducers

Avoid the use of concomitant strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital). If patients require co-administration of a strong CYP3A4 inducer, consider increasing the AFINITOR dose from 10 mg daily up to 20 mg daily (based on pharmacokinetic data), using 5 mg increments. This dose of AFINITOR is predicted to adjust the AUC to the range observed without inducers. However, there are no clinical data with this dose adjustment in patients receiving strong CYP3A4 inducers. If the strong inducer is discontinued, the AFINITOR dose should be returned to the dose used prior to initiation of the strong CYP3A4 inducer [see *Warnings and Precautions (5.6) and Drug Interactions (7.2)*].

Grapefruit, grapefruit juice and other foods that are known to inhibit cytochrome P450 and PgP activity may increase everolimus exposures and should be avoided during treatment. St. John's Wort (*Hypericum perforatum*) may decrease everolimus exposure unpredictably and should be avoided.

2.3 Recommended Dose in Subependymal Giant Cell Astrocytoma

The recommended starting dose of AFINITOR for treatment of patients with SEGA is according to Table 1:

Table 1: Recommended Starting Dose of AFINITOR for Treatment of Patients with SEGA

Body Surface Area (BSA)	Starting Dose
0.5 m ² to 1.2 m ²	2.5 mg once daily
1.3 m ² to 2.1 m ²	5 mg once daily
Greater than or equal to 2.2 m ²	7.5 mg once daily

Patients receiving AFINITOR may require dose adjustments based on everolimus trough blood concentrations achieved, tolerability, individual response, and change in concomitant medications including CYP3A4-inducing antiepileptic drugs [see *Warnings and Precautions (5.6) and Drug Interactions (7.1, 7.2)*]. Dose adjustments can be made at two week intervals [See *Dosage and Administration (2.4, 2.5)*].

Evaluate SEGA volume approximately 3 months after commencing AFINITOR therapy and periodically thereafter, with subsequent dose adjustments taking into consideration changes in SEGA volume, corresponding trough concentration, and tolerability. Responses have been observed at trough concentrations as low as 3 ng/mL; as such, once acceptable efficacy has been achieved, additional dose increases may not be necessary.

AFINITOR has not been studied in patients with SEGA < 3 years of age or with BSA < 0.58 m².

The optimal duration of therapy for patients with SEGA is unknown.

2.4 Dose Modifications in Subependymal Giant Cell Astrocytoma

Management of severe or intolerable adverse reactions may require temporary dose reduction and/or interruption of AFINITOR therapy [see *Warnings and Precautions (5.1)*]. If dose reduction is required for patients receiving 2.5 mg daily, consider alternate day dosing.

CYP3A4 and/or P-glycoprotein (PgP) Inhibitors

Avoid the use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) [see *Warnings and Precautions (5.5) and Drug Interactions (7.1)*].

Use caution when co-administered with moderate CYP3A4 and/or PgP inhibitors (e.g., amprenavir, fosamprenavir, aprepitant, erythromycin, fluconazole, verapamil, diltiazem). If patients require co-administration of a moderate CYP3A4 and/or PgP inhibitor, reduce the AFINITOR dose by approximately 50% to maintain trough concentrations of 5 to 10 ng/mL. If dose reduction is required for patients receiving 2.5 mg daily, consider alternate day dosing. Subsequent dosing should be individualized based on therapeutic drug monitoring. Everolimus trough concentrations should be assessed approximately 2 weeks after the addition of a moderate CYP3A4 and/or PgP inhibitor. If the moderate inhibitor is discontinued, the AFINITOR dose should be returned to the dose used prior to initiation of the moderate CYP3A4 and/or PgP inhibitor and the everolimus trough concentration should be re-assessed approximately 2 weeks later [see *Warnings and Precautions (5.6) and Drug Interactions (7.1)*].

Strong CYP3A4 Inducers

Avoid the use of concomitant strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital). For patients requiring a concomitant strong CYP3A4 inducer, double the AFINITOR dose. Subsequent dosing should be individualized based on therapeutic drug monitoring. If the strong inducer is discontinued, the

trough concentrations should be assessed approximately 2 weeks later [see *Warnings and Precautions (5.6) and Drug Interactions (7.2)*].

Grapefruit, grapefruit juice and other foods that are known to inhibit cytochrome P450 and P-gP activity may increase everolimus exposures and should be avoided during treatment. St. John's Wort (*Hypericum perforatum*) may decrease everolimus exposure unpredictably and should be avoided.

2.5 Therapeutic Drug Monitoring in Subependymal Giant Cell Astrocytoma

Routine everolimus whole blood therapeutic drug concentration monitoring is recommended for all patients using a validated assay. Trough concentrations should be assessed approximately 2 weeks after commencing treatment. Dosing should be titrated to attain trough concentrations of 5 to 10 ng/mL.

There is limited safety experience with patients having trough concentrations > 10 ng/mL. If concentrations are between 10 to 15 ng/mL, and the patient has demonstrated adequate tolerability and tumor response, no dose reductions are needed. The dose of AFINITOR should be reduced if trough concentrations > 15 ng/mL are observed.

If concentrations are < 5 ng/mL, the daily dose may be increased by 2.5 mg every 2 weeks, subject to tolerability. Daily dose may be reduced by 2.5 mg every 2 weeks to attain a target of 5 to 10 ng/mL. If dose reduction is required for patients receiving 2.5 mg daily, alternate day dosing should be used.

Trough concentrations should be assessed approximately 2 weeks after any change in dose, or after an initiation or change in co-administration of CYP3A4 and/or P-gP inducers or inhibitors [see *Dosage and Administration (2.4), Warnings and Precautions (5.6), Drug Interactions (7.1, 7.2)*].

3 DOSAGE FORMS AND STRENGTHS

2.5 mg tablet

White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with "LCL" on one side and "NVR" on the other.

5 mg tablet

White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with "5" on one side and "NVR" on the other.

10 mg tablet

White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with "UHE" on one side and "NVR" on the other.

4 CONTRAINDICATIONS

Hypersensitivity to the active substance, to other rapamycin derivatives, or to any of the excipients. Hypersensitivity reactions manifested by symptoms including, but not limited to, anaphylaxis, dyspnea, flushing, chest pain, or angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment) have been observed with everolimus and other rapamycin derivatives.

5 WARNINGS AND PRECAUTIONS

5.1 Non-infectious Pneumonitis

Non-infectious pneumonitis is a class effect of rapamycin derivatives, including AFINITOR. Non-infectious pneumonitis was reported in 11-14% of patients treated with AFINITOR. The incidence of Common Terminology Criteria (CTC) grade 3 and 4 non-infectious pneumonitis was 1.6-4.0% and 0.1%, respectively [see *Adverse Reactions (6.1)*]. Fatal outcomes have been observed.

Consider a diagnosis of non-infectious pneumonitis in patients presenting with non-specific respiratory signs and symptoms such as hypoxia, pleural effusion, cough, or dyspnea, and in whom infectious, neoplastic, and other causes have been excluded by means of appropriate investigations. Advise patients to report promptly any new or worsening respiratory symptoms.

Patients who develop radiological changes suggestive of non-infectious pneumonitis and have few or no symptoms may continue AFINITOR therapy without dose alteration. Imaging appears to overestimate the incidence of clinical pneumonitis.

If symptoms are moderate, consider interrupting therapy until symptoms improve. The use of corticosteroids may be indicated.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.